| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0333102413499648 |
| P698 | PubMed publication ID | 23963355 |
| P50 | author | Claudia Sommer | Q64762189 |
| Andreas Straube | Q67209925 | ||
| Hans-Christoph Diener | Q25935337 | ||
| P2093 | author name string | Stefan Evers | |
| Ronald Brand | |||
| Tim P Jürgens | |||
| Hans O Kalkman | |||
| Martin Sommer | |||
| Baltazar Gomez-Mancilla | |||
| Donald Johns | |||
| Nicole Pezous | |||
| Victor Campos | |||
| Sam Hariry | |||
| BGG492 Study Group | |||
| Harmut Göbel | |||
| P2860 | cites work | Oral sumatriptan in the acute treatment of migraine and migraine recurrence in general practice | Q39463122 |
| Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors | Q48203873 | ||
| Effects of AMPA and clomethiazole on spreading depression cycles in the rat neocortex in vivo | Q48949015 | ||
| Effect of encapsulation on absorption of sumatriptan tablets: data from healthy volunteers and patients during a migraine | Q30646143 | ||
| Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1. | Q34023677 | ||
| LY293558, a novel AMPA/GluR5 antagonist, is efficacious and well-tolerated in acute migraine. | Q34326873 | ||
| Safety profile of the triptans | Q35194407 | ||
| Current practice and future directions in the prevention and acute management of migraine | Q37695402 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | migraine | Q133823 |
| multicenter clinical trial | Q6934595 | ||
| P304 | page(s) | 103-113 | |
| P577 | publication date | 2013-08-20 | |
| P1433 | published in | Cephalalgia | Q5063251 |
| P1476 | title | Randomized, multicenter trial to assess the efficacy, safety and tolerability of a single dose of a novel AMPA receptor antagonist BGG492 for the treatment of acute migraine attacks | |
| P478 | volume | 34 |
| Q38742593 | An update on migraine: current understanding and future directions. |
| Q48495487 | Bench to bedside advances in the 21st century for primary headache disorders: migraine treatments for migraine patients |
| Q38293380 | Clinical trials update 2014: year in review |
| Q28070254 | Current Status of the New Antiepileptic Drugs in Chronic Pain |
| Q48214672 | Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist. |
| Q38230246 | Glutamate receptor antagonists in the management of migraine |
| Q47627647 | Glutamate receptor antagonists with the potential for migraine treatment. |
| Q35532861 | Ionic liquid versus prodrug strategy to address formulation challenges |
| Q37208487 | Metabotropic glutamate receptor 5: a target for migraine therapy |
| Q38286465 | Migraine pathophysiology: lessons from mouse models and human genetics |
| Q30238764 | Minority Representation in Migraine Treatment Trials |
| Q46279239 | New targets for migraine therapy |
| Q34494441 | New therapeutic approaches for the prevention and treatment of migraine |
| Q35722682 | PRRT2 Mutant Leads to Dysfunction of Glutamate Signaling |
| Q39127073 | Pathophysiology of Migraine: A Disorder of Sensory Processing |
| Q93010752 | Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro |
| Q85941544 | [Pharmacological aspects of pain research in Germany] |
Search more.